Third Quarter Report 2024

SZSIOct 25 12:00 ET · Announcements

Hinova Pharmaceuticals Gets Regulatory Approval to Conduct Breast Cancer Clinical Trial

MT NewswiresOct 16 02:46 ET

Haisco Pharmaceutical (688302.SH): Yingchuang Power has cumulatively reduced its shareholding by 1%.

GeLongHui, October 14th | HaiChuang Pharmaceutical (688302.SH) announced that the company recently received a notice from YingChuang Power regarding the expiration of the shareholding reduction plan period and the results of the reduction. As of October 14, 2024, the current shareholding reduction plan period has expired. During the implementation of this shareholding reduction plan, YingChuang Power has cumulatively reduced 990,150 shares of the company's stock, accounting for 1.00% of the total share capital of the company.

Gelonghui FinanceOct 14 06:56 ET

Hinova Pharmaceuticals Inc. (SHSE:688302) Surges 23%; Individual Investors Who Own 33% Shares Profited Along With Institutions

Simply Wall StSep 19 18:35 ET

Half-year report for the year 2024.

SZSIAug 23 12:00 ET · Announcements

Summary of Half-Year Report in 2024.

SZSIAug 23 12:00 ET · Announcements